Adicet Bio, Inc.
ACET · Pharmaceutical Preparations · 9.3M shares · -44%/yr ↓ buyback · EDGAR filings ↗
Net buyback after stock comp: -$7M (gross $15M, SBC $22M)
Reference price $6.29 · est. market cap ~$59M — last insider sale, 2026-04-08 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — gamma-delta cell-therapy clinical, well-funded.
Strengths
- Liquidity — current ratio 7.5 (71st)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- No interest coverageInterest coverage -3392.06 (cannot cover interest)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC, FMR LLC, GOLDMAN SACHS GROUP INC
- Cash burnNegative free cash flow (-97.0M)
- Insider buyingInsider buying — 3 open-market buy(s) by 1 insider(s) (~$2M, last 6mo) Form 4 ↗
- Buying back stockNet buyback — share count -44%/yr over 3y
- Notable holderHeld by 3 notable fund(s): CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP (as of 2026-03-31)
- Insider sellingInsider selling — 4 open-market sale(s) by 1 insider(s) (~$674,847, last 6mo) Form 4 ↗
Key metrics
Return on equity
-73.4%
Return on assets
-60.7%
Interest coverage
-3392.1×
Current ratio
7.5×
Free cash flow
-$97M
EBITDA
-$116M
Tangible book value
$159M
Cash & investments
$39M
Cash runway
2q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | Other | 250K | — |
| 2026-04-08 | ORBIMED ADVISORS LLC | Sell | 40K | $6.52 |
| 2026-04-08 | ORBIMED ADVISORS LLC | Sell | 33K | $6.29 |
| 2026-04-07 | ORBIMED ADVISORS LLC | Sell | 29K | $6.53 |
| 2026-04-07 | ORBIMED ADVISORS LLC | Sell | 2.4K | $6.38 |
| 2026-02-20 | RA CAPITAL MANAGEMENT, L.P. | Buy | 75K | $7.27 |
| 2026-02-19 | RA CAPITAL MANAGEMENT, L.P. | Buy | 74K | $7.21 |
| 2026-02-18 | RA CAPITAL MANAGEMENT, L.P. | Buy | 75K | $7.04 |
| 2026-01-24 | Harvey Brian Nicholas | Tax withheld | 546 | $8.44 |
| 2026-01-24 | Aftab Blake | Tax withheld | 535 | $8.44 |
| 2026-01-24 | Healey Don | Tax withheld | 535 | $8.44 |
| 2026-01-24 | Schor Chen | Tax withheld | 1.8K | $8.44 |
| 2025-10-08 | ORBIMED ADVISORS LLC | Buy | 1.5M | $1.00 |
| 2025-10-08 | ORBIMED ADVISORS LLC | Buy | 3.5M | $1.00 |
| 2025-06-11 | Klickstein Lloyd | Grant | 5.9K | — |
| 2025-06-11 | Chodakewitz Jeffrey | Grant | 5.9K | — |
| 2025-06-11 | DUBIN STEVE | Grant | 5.9K | — |
| 2025-06-11 | Peng Katie | Grant | 5.9K | — |
| 2025-06-11 | Sinclair Andrew | Grant | 5.9K | — |
| 2025-01-24 | Schor Chen | Tax withheld | 28K | $0.92 |
| 2025-01-24 | Healey Don | Tax withheld | 8.6K | $0.92 |
| 2025-01-24 | Aftab Blake | Tax withheld | 6.3K | $0.92 |
| 2025-01-24 | Harvey Brian Nicholas | Tax withheld | 8.8K | $0.92 |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-17 | 0001720580-26-000043 ↗ |
| 10-K/A | 2026-05-20 | 2025-12-31 | 0001720580-26-000042 ↗ |
| 8-K | 2026-05-13 | 2026-05-13 | 0001720580-26-000036 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001720580-26-000037 ↗ |
| 8-K | 2026-04-28 | 2026-04-27 | 0001720580-26-000023 ↗ |
| 8-K | 2026-03-12 | 2026-03-12 | 0001720580-26-000006 ↗ |
| 10-K | 2026-03-12 | 2025-12-31 | 0001720580-26-000008 ↗ |
| 8-K | 2026-01-07 | 2026-01-07 | 0001193125-26-005486 ↗ |
| 8-K | 2025-12-29 | 2025-12-26 | 0001193125-25-332343 ↗ |
| 8-K | 2025-12-19 | 2025-12-19 | 0001193125-25-326784 ↗ |
| 10-Q | 2025-11-05 | 2025-09-30 | 0001193125-25-266880 ↗ |
| 8-K | 2025-11-05 | 2025-11-05 | 0001193125-25-266860 ↗ |